Oncobiologics (OTLK) Earnings Date, Estimates & Call Transcripts $2.68 +0.27 (+11.20%) Closing price 04:00 PM EasternExtended Trading$2.65 -0.03 (-1.12%) As of 05:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Oncobiologics Earnings Summary Oncobiologics released Q3 2025 earnings on August 14, 2025, reporting an EPS of -$0.44, which missed the consensus estimate of -$0.42 by $0.02. Quarterly revenue was reported to be $1.51 million, below analyst estimates of $1.66 million. With a trailing EPS of -$0.57, Oncobiologics' earnings are expected to grow next year, from ($2.27) to ($0.20) per share. Latest Q3 Earnings DateAug. 14EstimatedConsensus EPS (Aug. 14) -$0.42 Actual EPS (Aug. 14) -$0.44 Missed By -$0.02 Actual Revenue (Aug. 14) $1.51MQ3 2025 Earnings ResourcesQ3 2025 Earnings Report Press Release (8-K) Quarterly Report (10-Q)Powered by Get Oncobiologics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Oncobiologics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataOTLK Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter. Oncobiologics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20252-$0.99-$0.70-$0.85Q2 20252-$0.60-$0.53-$0.57Q3 20252-$0.51-$0.29-$0.40Q4 20251-$0.22-$0.22-$0.22 Oncobiologics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails8/14/2025Q3 2025-$0.42-$0.44 -$0.02-$0.55$1.66M$1.51M5/15/2025Q2 2025-$0.55-$0.40+$0.15-$1.50$0.70M-2/14/2025Q1 2025-$0.85-$0.89 -$0.04$0.72--12/27/2024Q4 2024-$0.83-$0.77+$0.06$0.76--8/14/2024Q3 2024-$1.06-$0.83+$0.23-$0.77--5/15/2024Q2 2024-$0.88-$1.55 -$0.67$4.91--2/14/2024Q1 2024-$1.00-$0.80+$0.20-$0.04--12/22/2023Q4 2023-$1.00-$1.00--$0.05-- Oncobiologics Earnings - Frequently Asked Questions When did Oncobiologics announce their last quarterly earnings? Oncobiologics (NASDAQ:OTLK) last announced its quarterly earning data on Thursday, August 14, 2025. Learn more on OTLK's earnings history. Did Oncobiologics beat their earnings estimates last quarter? In the previous quarter, Oncobiologics (NASDAQ:OTLK) missed the analysts' consensus estimate of ($0.42) by $0.02 with a reported earnings per share (EPS) of ($0.44). Learn more on analysts' earnings estimate vs. OTLK's actual earnings. How much profit does Oncobiologics generate each year? Oncobiologics (NASDAQ:OTLK) has a recorded net income of -$75.37 million. OTLK has generated -$0.57 earnings per share over the last four quarters. What is Oncobiologics' EPS forecast for next year? Oncobiologics' earnings are expected to grow from ($2.27) per share to ($0.20) per share in the next year. More Earnings Resources from MarketBeat Related Companies ADC Therapeutics Earnings Fulcrum Therapeutics Earnings Abeona Therapeutics Earnings Capricor Therapeutics Earnings Tonix Pharmaceuticals Earnings CytomX Therapeutics Earnings Inhibrx Biosciences Earnings 4D Molecular Therapeutics Earnings Amarin Earnings Benitec Biopharma Earnings Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles After Earnings Miss, Walmart Is Still a Top Consumer Staples PlayDLocal Stock Soars 43% After Earnings Beat and Raised GuidanceGreen Dot's 30% Rally: Turnaround Takes Off on Explosive EarningsElbit Systems Jumps on Record Earnings and a $1.6B ContractBrinker Serves Up Earnings Beat, Sidesteps Cost PressuresWhy BigBear.ai Stock's Dip on Earnings Can Be an Opportunity CrowdStrike Faces Valuation Test Before Key Earnings Report This page (NASDAQ:OTLK) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersOne tiny company just cracked Google’s $19B problemGoogle, Microsoft, IBM… every major AI player will be forced to secure massive amounts of this material just t...True Market Insiders | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredBREAKING: The House just passed 3 pro-crypto bills!The “top secret” DeFi play Our #1 Coin Report reveals which protocol is building this institutional bridge...Crypto 101 Media | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredCould This Be the End of Retirement Worries?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncobiologics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncobiologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access